Creative Medical Technology (CELZ) announced one-year follow-up data from the AlloStem Type 2 Diabetes pilot study for late-stage patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback